Want to see FR:ALNEV full AI Analyst Report?
Top Page
Neovacs SA
(ALNEV)
Select Model
Select Model
Rating:43Neutral
Price Target:
€0.20
▲(1930.00% Upside)
Action:Reiterated
Date:09/30/26
The score is weighed down primarily by weak financial performance—persistent losses, negative cash generation, and volatile/declining revenue—despite low reported leverage. Technicals also detract due to clear bearish momentum (below key moving averages, negative MACD), while valuation provides limited support given the non-meaningful P/E and lack of dividend yield.
Positive Factors
Low Financial Leverage
Very low reported leverage reduces refinancing pressure and leaves more financial flexibility than a heavily indebted biotechnology company would have. This can help Neovacs preserve strategic options and absorb operating volatility, although it does not eliminate the need to fund ongoing losses.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that the current business has not reached an economically sustainable scale. Continued losses can erode shareholder capital, constrain investment in research programs, and make future success increasingly dependent on financing or commercial milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low reported leverage reduces refinancing pressure and leaves more financial flexibility than a heavily indebted biotechnology company would have. This can help Neovacs preserve strategic options and absorb operating volatility, although it does not eliminate the need to fund ongoing losses.
Read all positive factors
Neovacs SA (ALNEV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€33.44K
Dividend YieldN/A
Average Volume (3M)46.88K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue Growth-44.46%
EPS Growth100.00%
CountryFR
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-51100.07
Shares Outstanding159,064
10 Day Avg. Volume34,551
30 Day Avg. Volume46,878
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neovacs SA Business Overview & Revenue Model
Company Description
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages it...
How the Company Makes Money
Neovacs’ business model is primarily biotechnology R&D-driven. The company would be expected to generate revenue through (1) out-licensing or co-development agreements for its Kinoid platform and/or individual drug candidates, typically structured...
Neovacs SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 161.78K | 366.35K | 533.41K | 1.11K | 22.59K |
| Gross Profit | -4.52M | 42.42K | -6.75M | -6.26M | -7.60M |
| EBITDA | -5.24M | -6.61M | -8.45M | -3.61M | -10.38M |
| Net Income | -4.90M | -32.91M | -8.74M | -3.55M | -11.84M |
Balance Sheet | |||||
| Total Assets | 22.14M | 22.07M | 47.53M | 49.28M | 48.55M |
| Cash, Cash Equivalents and Short-Term Investments | 571.79K | 435.45K | 887.09K | 6.76M | 33.09M |
| Total Debt | 537.20K | 230.37K | 650.59K | 1.20M | 1.03M |
| Total Liabilities | 4.10M | 4.01M | 3.71M | 5.05M | 4.65M |
| Stockholders Equity | 18.03M | 18.06M | 43.82M | 44.23M | 43.90M |
Cash Flow | |||||
| Free Cash Flow | -5.04M | -3.68M | -2.12M | -4.60M | -10.26M |
| Operating Cash Flow | -5.03M | -3.60M | -1.91M | -4.45M | -9.91M |
| Investing Cash Flow | -446.17K | 1.45M | -11.08M | -31.56M | -18.81M |
| Financing Cash Flow | 5.62M | 1.70M | 6.79M | 9.99M | 51.75M |
Neovacs SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €202.87M | -4.32 | -29.36% | ― | 189.81% | 38.50% | |
47 Neutral | €509.58M | -3.02 | -152.15% | ― | -27.19% | -117.39% | |
44 Neutral | €7.32B | -17.95 | -85.88% | ― | ― | ― | |
43 Neutral | €33.44K | ― | -26.52% | ― | -44.46% | 100.00% | |
43 Neutral | €634.32M | -2.95 | -119.47% | ― | ― | 41.33% | |
41 Neutral | €52.99M | -1.37 | -96.73% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
FR:ALNEV
Neovacs SA
0.21
-1,775.79
-99.99%
FR:ABVX
Abivax SA
83.85
11.95
16.62%
FR:DBV
DBV Technologies
2.02
0.34
20.26%
FR:TNG
Transgene
0.73
-0.42
-36.61%
FR:VLA
Valneva
2.69
-2.27
-45.74%
FR:OSE
OSE Immunotherapeutics SA
2.25
-4.50
-66.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.